Pyc Therapeutics Limited · ASX:PYC
Pyc Therapeutics — E&P Healthcare Conference 2024
9 slides from Pyc Therapeutics's conference presentation, Sep 26, 2024
Slide 1: E&P Healthcare Conference Presentation
26 31 September October 2024 2022 E&P HEALTHCARE CONFERENCE PRESENTATION PERTH, Australia and SAN FRANCISCO, California – 26 September 2024 PYC Therapeutics Limited (ASX:PYC) is pleased to provide a copy of the presentation that will be given by PYC’s CEO, Dr Rohan Hockings, at the E&P Healthcare Co
Slide 2: Contacts: Investors and Media
CONTACTS: INVESTORS and MEDIA info@pyctx.com For personal use only pyctx.com | ACN 098 391 961 2
Slide 3: Life-changing science
For personal use only Life-changing science E&P Healthcare Conference September 2024
Slide 4: Disclaimer
Disclaimer The purpose of this presentation is to provide an update of the business which are outside PYC’s control. Important factors that could cause For personal use only of PYC Therapeutics Limited (ASX:PYC) [‘PYC’]. These slides have been actual results to differ materially from assumptions or
Slide 5: PYC will deliver multiple human data read-outs over the next 18 months
PYC will deliver multiple human data read-outs for drug candidates with best-in-class potential over the next 18 months1 PYC’s path to market is staged with human data read-outs for first-in-class drugs with disease-modifying potential1 For personal use only Program 2024 2025 2026 2027 2028 RP11 Ph1
Slide 6: Efficacy data from RP11 trials and PKD pre-clinical data pack headline Q4 2024 milestones
Efficacy data from the RP11 trials and the complete pre- clinical data pack in PKD headline PYC’s Q4 2024 milestones1 Program October November December For personal use only RP11 VP-001 Human safety and efficacy data Monogenic blinding eye disease of childhood (multiple dose studies) Gene: PRPF31 AD
Slide 7: Robust data from multiple dose studies in RP11 will define a path to market
Robust data from the multiple dose studies in RP11 will define a path to market for this drug candidate Improved retinal function following treatment with VP-001 For personal use only Retinal sensitivity as assessed by microperimetry (MP) in SAD cohort 3 and 4 patients over time 4 3 I Change from Ba
Slide 8: PYC's immediate objective is to deliver 'very good' data in ongoing RP type 11 studies
PYC’s immediate objective is to deliver ‘very good’ data1 in the ongoing multiple dose studies in RP type 112 For personal use only 1. Stifel biopharma market update 9 September 2024 https://www.stifel.com/newsletters/investmentbanking/bal/marketing/healthcare/biopharma_timopler/biopharmamarketupdat
Slide 9: The FDA is looking to accelerate approvals of gene therapies for rare diseases
The FDA is looking to accelerate approvals of gene therapies for rare diseases specifically For personal use only “There are a lot of gene therapies for rare diseases that are almost there” “And it’s a question of, how do we get them across the finish line?”1 1. Peter Marks in Endpoints News intervi